10-Q: Cabaletta Bio Advances Autoimmune CAR T Pipeline

Cabaletta Bio reports increased R&D spend and net losses, fueled by promising clinical data for its lead CAR T candidate rese-cel and a significant capital raise.

Summary

• Net loss increased to $81.1 million for the six months ended June 30, 2025, compared to $52.6 million for the same period in 2024, primarily due to increased research and development expenses.
• Research and development expenses rose by $21.3 million to $66.7 million for the six months ended June 30, 2025, driven by expanded cell processing capabilities, increased patient enrollment, and commercial readiness activities.
• General and administrative expenses increased by $3.5 million to $16.4 million for the six months ended June 30, 2025, mainly due to increased headcount and administrative costs.
• The company successfully completed a June 2025 financing, raising $93.6 million in net proceeds from the issuance of common stock and warrants, extending its cash runway into the second half of 2026.
• As of June 30, 2025, cash, cash equivalents, and investments totaled $194.7 million, with an accumulated deficit of $430.2 million.
• Positive interim clinical and translational data for rese-cel were presented from 18 evaluable patients across RESET-Myositis™, RESET-SLE™, and RESET-SSc™ trials, showing high rates of clinical response and favorable safety profiles (94% no CRS or Grade 1 CRS, 89% no ICANS).
• Rese-cel received Regenerative Medicine Advanced Therapy (RMAT) designation for myositis in May 2025, and Fast Track designations for dermatomyositis, systemic sclerosis, SLE, and multiple sclerosis.
• Plans are in place to initiate registrational cohort enrollment for rese-cel in myositis in the second half of 2025, targeting a Biologics License Application (BLA) submission in 2027.
• Five 6-patient Phase 1/2 disease cohorts for rese-cel are fully enrolled across the RESET™ clinical development program as of July 31, 2025.
• New manufacturing agreements with Lonza Houston Inc. and an expanded partnership with Cellares Corp. are advancing manufacturing capabilities for rese-cel.

Sentiment

Score: 8

Explanation: The company demonstrates strong clinical progress with its lead candidate, rese-cel, securing multiple expedited regulatory designations and reporting positive interim clinical data across several autoimmune indications. A significant capital raise has extended its financial runway, providing crucial support for ongoing development. While net losses have increased, this is an expected outcome of aggressive R&D investment in a clinical-stage biotech. The clear path towards registrational trials and advancements in manufacturing capabilities indicate a positive trajectory, despite inherent industry risks and the going concern warning.

Positives

• Strong interim clinical data for rese-cel across multiple autoimmune indications (Myositis, SLE, SSc) demonstrating high rates of clinical response and a favorable safety profile, with 94% of patients experiencing no CRS or Grade 1 CRS and 89% experiencing no ICANS.
• Rese-cel received Regenerative Medicine Advanced Therapy (RMAT) designation for myositis, indicating potential for expedited development and review by the FDA.
• Multiple Fast Track designations for rese-cel in dermatomyositis, systemic sclerosis, SLE, and relapsing/progressive MS, and Orphan Drug designations for myositis and systemic sclerosis, highlight significant unmet medical needs and potential for accelerated regulatory pathways.
• A successful June 2025 financing raised $93.6 million in net proceeds, significantly extending the cash runway into the second half of 2026.
• Strategic manufacturing partnerships with Lonza and Cellares Corp. are progressing, with the Lonza process slated for use in initiating registrational trial enrollment, signaling advancement towards commercial readiness.
• Five 6-patient Phase 1/2 disease cohorts for rese-cel are fully enrolled across the RESET™ clinical development program as of July 31, 2025.
• Alignment with the FDA on registrational cohort design for myositis, with plans to initiate enrollment in the second half of 2025 and target BLA submission in 2027.

Negatives

• Net loss significantly increased to $81.1 million for the six months ended June 30, 2025, compared to $52.6 million in the prior year, indicating a higher cash burn rate.
• Interest income decreased by $2.8 million for the six months ended June 30, 2025, primarily due to lower cash and investment balances.
• The company has incurred substantial losses since its inception, with an accumulated deficit of $430.2 million as of June 30, 2025, and anticipates continued significant losses.
• Substantial doubt exists about the company's ability to continue as a going concern beyond the second half of 2026 without securing additional funding.
• The MusCAARTes™ trial (MuSK-CAART) is not actively enrolling patients at this time.
• The FDA's ongoing investigation into T-cell malignancies following treatment with BCMAor CD19-directed CAR T cell immunotherapies requires life-long monitoring for rese-cel patients, introducing a significant safety concern.

Risks

• The company is a clinical-stage entity with a limited operating history, has incurred significant losses since inception, and anticipates continued substantial losses for the foreseeable future.
• High dependence on third-party manufacturing partners (University of Pennsylvania, Minaris Advanced Therapies, Lonza Houston Inc.); any reduction, delay, or limitation in manufacturing capacity could adversely impact product supply and trial enrollment.
• Reliance on intellectual property licensed from the University of Pennsylvania and Nanjing IASO Biotherapeutics Co., Ltd.; termination of these license agreements would result in the loss of significant rights.
• Inability to obtain and maintain sufficient intellectual property protection for current or future product candidates could hinder effective competition.
• Substantial additional funding will be required to complete product development or generate revenue; current cash runway extends only into the second half of 2026, raising substantial doubt about the company's ability to continue as a going concern without further financing.
• Potential difficulties in enrolling patients in RESET™ clinical trials or future clinical trials, which could delay or adversely affect clinical development activities.
• Risk of significant delays or inability to advance product candidates through clinical development, obtain regulatory approval, and ultimately commercialize them.
• Results of earlier studies may not be predictive of future study or trial results, and the company may fail to establish an adequate safety and efficacy profile to conduct clinical trials or obtain regulatory approval.
• Identification of serious adverse events, undesirable side effects (e.g., Cytokine Release Syndrome (CRS), Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)), or unexpected characteristics during development could necessitate delays, abandonment, or limitation of further clinical development.
• Manufacturing and administering product candidates is complex, and the company may encounter difficulties in technology transfer to contract manufacturing organizations.
• Substantial competition from other biotechnology and pharmaceutical companies may result in others discovering, developing, or commercializing products before or more successfully.
• The company may establish its own manufacturing facility, which would be costly, time-consuming, and may not be successful.
• Future success depends in part upon the ability to retain key employees, consultants, and advisors, and to attract, retain, and motivate other qualified personnel.
• Business disruptions, including due to natural disasters, global conflicts or political unrest, could seriously impact operations, research, and trials.
• The increasing use of social media platforms presents new risks and challenges, including potential non-compliance with adverse event reporting obligations or inappropriate promotion.
• The regulatory approval process is lengthy, time-consuming, and uncertain, especially for novel cellular therapies, with potential for changes in regulatory requirements or policies.
• Product candidates, if approved, are expected to be regulated as biological products and may be subject to competition from biosimilars.
• Orphan drug designation and rare pediatric disease priority review vouchers, even if granted, may not lead to faster development or approval, or may be limited or sunset.
• Ongoing regulatory obligations and continued regulatory review post-approval may result in significant additional expense and potential penalties for non-compliance.
• Failure to comply with environmental, health, and safety laws and regulations could lead to fines or penalties.
• Employees, independent contractors, consultants, commercial partners, and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and healthcare fraud and abuse laws.
• Healthcare coverage and reimbursement may be limited or unavailable, making it difficult to sell product candidates profitably if licensed.
• The company may become involved in lawsuits to protect or enforce its patent rights or other intellectual property rights, which could be expensive, time-consuming, and unsuccessful.
• Changes in tax laws could adversely affect the business and financial condition.
• The ability to utilize net operating losses and certain other tax attributes to offset future taxable income may be subject to limitations.
• Adverse developments affecting the financial services industry could adversely affect current and projected business operations.
• The price of the company's stock may be volatile, and stockholders could lose all or part of their investment.
• Anti-takeover provisions under charter documents and Delaware law could delay or prevent a change of control.
• Designation of certain courts as the sole and exclusive forum for certain types of actions could limit stockholders' ability to obtain a favorable judicial forum.

Future Outlook

The company anticipates continued significant losses for the foreseeable future as it invests in research and development, clinical trials, and manufacturing. Current cash, cash equivalents, and investments are expected to fund operations into the second half of 2026. The company plans to initiate registrational cohort enrollment for rese-cel in myositis in the second half of 2025, targeting a Biologics License Application (BLA) submission in 2027. Alignment with the FDA on registrational cohort designs for SLE/LN, SSc, and MG is anticipated in 3Q25, 4Q25, and 1H26, respectively. Initial dose data from the RESET-PV™ trial is expected in 2H25. The company will continue to seek additional funding through equity offerings, debt financings, or strategic collaborations to support its business plan and ongoing operations.

Management Comments

• We are a clinical-stage biotechnology company focused on the discovery and development of innovative engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases.
• We believe our CABA platform has the potential to safely enable complete and durable responses for a broad range of autoimmune diseases and that it has potential applicability across dozens of autoimmune diseases that we have identified, evaluated and prioritized.
• We are planning to implement the following design for two single-arm, sub-type disease-specific registrational cohorts in the ongoing RESET-Myositis™ trial, either of which, if successful, enable a future Biologics License Application, or BLA, submission for rese-cel in myositis.
• We believe that together, these two cohorts have the potential to support a broad label to address many of the approximately 80,000 myositis patients in the U.S., including those with or without a history of IVIg use.
• We also aligned with the FDA on combining the Phase 1/2 DM & ASyS cohorts into a single cohort designed to treat six patients with either DM or ASyS.
• We anticipate aligning with the FDA on the registrational cohort design for studies in SLE/LN in 3Q25.
• We anticipate aligning with the FDA on the registrational cohort design for studies in SSc in 4Q25.
• We anticipate aligning with the FDA on the registrational cohort design for studies in MG in 1H26.
• We anticipate sharing initial dose data from the RESET-PV™ trial in 2H25.
• Our aim is to achieve full manufacturing readiness through expanded CDMO relationships, establishment of our own manufacturing facilities, and/or through strategic partnership(s).
• We expect that our current cash, cash equivalents and investments may not be sufficient to fund operations for at least the next twelve months from the date of issuance of these unaudited condensed consolidated financial statements.
• Accordingly, substantial doubt exists about the company’s ability to continue as a going concern.
• We will continue to seek funds through equity offerings, debt financings or other capital sources, including potentially collaborations, licenses and other similar arrangements.

Industry Context

The company operates in the highly competitive and rapidly evolving biotechnology and pharmaceutical industries, specifically pioneering engineered T cell therapies for autoimmune diseases. This is a novel and high-risk area, as no cellular immunotherapies are currently licensed in the U.S. or EU for autoimmune conditions, distinguishing the company from oncology-focused CAR T developers like Novartis (Kymriah) and Gilead Sciences (Yescarta). The industry faces increasing regulatory scrutiny, particularly regarding T-cell malignancies associated with CAR T therapies, and ongoing pressures from cost containment measures and geopolitical tensions affecting global supply chains. The company's strategy to pursue multiple indications and secure expedited regulatory designations reflects the industry's drive to address significant unmet medical needs in serious diseases.

Comparison to Industry Standards

• There are no cellular immunotherapies currently licensed in the United States or the European Union specifically for the treatment of autoimmune diseases or alloimmune responses, making direct comparisons to approved products in this specific therapeutic area not applicable.
• While oncology CAR T therapies like Kymriah (Novartis Pharmaceuticals Corporation) and Yescarta (Gilead Sciences, Inc.) exist, the FDA's requirements for approval of cell therapies in autoimmune indications are not directly comparable, as the benefit-risk assessment thresholds are expected to be different given the non-life-threatening nature of many autoimmune conditions.
• The reported safety profile for rese-cel (94% no CRS or Grade 1 CRS, 89% no ICANS in 18 evaluable patients) appears favorable compared to the more severe and frequent CRS and ICANS events often observed with CAR T therapies in oncology, which is a critical advantage for autoimmune applications where patient tolerance for adverse events is lower.
• The company's receipt of Regenerative Medicine Advanced Therapy (RMAT), Fast Track, and Orphan Drug designations for rese-cel across various autoimmune indications demonstrates regulatory recognition of the significant unmet medical need and the potential for expedited development, aligning with industry trends to accelerate therapies for serious conditions.

Corporate Governance

Legal Proceedings

• As of June 30, 2025, the company is not involved in any material litigation or legal proceedings that it would expect to have a material adverse impact on its financial position, results of operations, or cash flows.
• The company was previously subject to a securities class action lawsuit filed in February 2022, which was voluntarily dismissed by the plaintiff in October 2022.

Related Party Transactions

• The company has a license agreement with the University of Pennsylvania (Penn) and Children's Hospital of Philadelphia (CHOP) for intellectual property, involving annual license maintenance fees and potential milestone payments and royalties.
• The company has Master Translational Research Services Agreements with Penn for research, development, and manufacturing services, with recognized expenses of $2,232,000 and $3,274,000 for the three and six months ended June 30, 2025, respectively.
• The company is committed to pay up to a remaining $1,500,000 under the CARTA Services Agreement for cell processing manufacturing through December 31, 2025.

Stakeholder Impact

• Shareholders: Potential for dilution from future capital raises, but also potential for significant value appreciation if product candidates achieve regulatory approval and commercial success. Stock option repricing aims to align employee incentives with shareholder value.
• Employees: Stock option repricing and continued investment in R&D and personnel aim to attract, retain, and motivate qualified staff, but the 'going concern' warning introduces uncertainty regarding long-term stability without further funding.
• Customers (future patients): Positive interim clinical data and expedited regulatory designations for rese-cel offer hope for new, potentially curative, treatment options for severe autoimmune diseases.
• Suppliers/Creditors: Continued reliance on third-party manufacturers (Penn, Minaris, Lonza, Oxford Biomedica) and other vendors for materials and services, indicating ongoing business for these partners. The company's financial health and ability to secure future funding will impact its relationships with creditors.
• Regulatory Authorities: Ongoing engagement with the FDA (e.g., RMAT, Fast Track, Type C meetings) and other international agencies (Health Canada, EMA) for clinical trial authorizations and regulatory approvals, demonstrating compliance and collaboration.

Next Steps

• Initiate registrational cohort enrollment for rese-cel in myositis in the second half of 2025.
• Target Biologics License Application (BLA) submission for rese-cel in myositis in 2027.
• Anticipate aligning with the FDA on registrational cohort design for studies in SLE/LN in 3Q25.
• Anticipate aligning with the FDA on registrational cohort design for studies in SSc in 4Q25.
• Anticipate aligning with the FDA on registrational cohort design for studies in MG in 1H26.
• Share initial dose data from the RESET-PV™ trial in the second half of 2025.
• Continue to seek additional funding through equity offerings, debt financings, or strategic alliances to support future operations beyond the second half of 2026.
• Continue to advance BLA readiness activities for lentiviral vector supply with Oxford Biomedica.
• Potentially incorporate Cellares Cell Shuttle™ automated manufacturing platform into clinical and commercial manufacturing strategy for rese-cel.

Key Dates

Recommendation

Cabaletta Bio, a clinical-stage biotechnology company, presents a compelling investment opportunity for investors with a high-risk tolerance. While the company reported increased net losses, this is a typical and expected characteristic of a biotech aggressively advancing its pipeline. The recent $93.6 million capital raise significantly strengthens its financial position, providing a runway into the second half of 2026, which is critical for continued operations. The most significant positive is the highly promising interim clinical data for its lead CD19-CAR T candidate, rese-cel, across multiple autoimmune indications, demonstrating favorable safety and efficacy. The receipt of Regenerative Medicine Advanced Therapy (RMAT), Fast Track, and Orphan Drug designations from the FDA underscores the significant unmet medical need and the potential for expedited regulatory pathways. The clear roadmap towards BLA submission for myositis in 2027, coupled with strategic advancements in manufacturing partnerships, indicates strong execution and a compelling long-term growth opportunity.

Keywords

Biotechnology, Cell Therapy, Autoimmune Disease, CAR T, Rese-cel, CABA-201, Clinical Trials, RESET-Myositis, RESET-SLE, RESET-SSc, RESET-MG, RESET-PV, RESET-MS, FDA, RMAT, Fast Track, Orphan Drug, SEC Filing, 10-Q, Biologics, Immunotherapy, CD19